Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prognostic value of GLCE and infiltrating immune cells in Ewing sarcoma. | Heliyon | 2023 | 37662777 | PubTator, text mining | PubMed |
| RBFOX2 recognizes N6-methyladenosine to suppress transcription and block myeloid leukaemia differentiation. | Nat Cell Biol | 2023 | 37640841 | PubTator, text mining | PubMed |
| Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer. | Front Immunol | 2023 | 37638051 | PubTator, text mining | PubMed |
| Changes in m6A in Steatotic Liver Disease. | Genes (Basel) | 2023 | 37628704 | PubTator, text mining | PubMed |
| Cuproptosis- and m6A-Related lncRNAs for Prognosis of Hepatocellular Carcinoma. | Biology (Basel) | 2023 | 37626987 | PubTator, text mining | PubMed |
| Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy. | Discov Oncol | 2023 | 37624511 | PubTator, text mining | PubMed |
| Methylation across the central dogma in health and diseases: new therapeutic strategies. | Signal Transduct Target Ther | 2023 | 37620312 | PubTator, text mining | PubMed |
| Characterization of m6A modifiers and RNA modifications in uterine fibroids. | bioRxiv | 2023 | 37609293 | PubTator, text mining | PubMed |
| The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma. | Diagn Pathol | 2023 | 37608295 | PubTator, text mining | PubMed |
| miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis. | Sci Rep | 2023 | 37604948 | PubTator, text mining | PubMed |
| The implications of N6-methyladenosine (m6A) modification in esophageal carcinoma. | Mol Biol Rep | 2023 | 37598390 | PubTator, text mining | PubMed |
| m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia. | BMC Med Genomics | 2023 | 37596597 | PubTator, text mining | PubMed |
| RNA modification-mediated translational control in immune cells. | RNA Biol | 2023 | 37584554 | PubTator, text mining | PubMed |
| m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism. | Mol Cancer | 2023 | 37582735 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma. | BMC Genom Data | 2023 | 37568073 | PubTator, text mining | PubMed |
| Analysis of the role of glucose metabolism-related genes in dilated cardiomyopathy based on bioinformatics. | J Thorac Dis | 2023 | 37559624 | PubTator, text mining | PubMed |
| Reinvestigating the clinical relevance of the m6A writer METTL3 in urothelial carcinoma of the bladder. | iScience | 2023 | 37554463 | PubTator, text mining | PubMed |
| Role of TNF-α-induced m6A RNA methylation in diseases: a comprehensive review. | Front Cell Dev Biol | 2023 | 37554306 | PubTator, text mining | PubMed |
| The crucial roles of m6A RNA modifications in cutaneous cancers: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies. | Genes Dis | 2023 | 37554186 | PubTator, text mining | PubMed |
| Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. | Oncol Res | 2023 | 37547754 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=11